Grid Biosciences Announces License Agreement with NIH for Epstein-Barr Virus Vaccine
NEW YORK, Aug. 29, 2022 /PRNewswire-PRWeb/ -- Grid Biosciences ("Grid"), a biotechnology company, today announced the signing of a license agreement for the development of a vaccine against Epstein-Barr virus ("EBV") with the National Institute of Allergy and Infectious Diseases ("NIAID"), part of the National Institutes of Health ("NIH"). The agreement includes access to NIH's patent rights in EBV envelope proteins that the virus uses to gain entry into human cells.